Cell and Gene Therapy

Phase I trial of NK cell therapy in advanced Alzheimer’s disease

All-in-one AAV vector for epigenome editing shows efficient APOE downregulation in vivo

Benefits of an all-in-one AAV CRISPR/Cas9 system for genome/epigenome editing

Novel genome editing approaches under investigation in Alzheimer’s disease

TDP-43 aggregation drives loss of UNC13A, a risk gene for ALS & FTD

Viral-mediated gene therapy for neurodegenerative disease

Improving the precision and safety of CRISPR/Cas genome editing

Developing APOE-targeted epigenome therapy for the treatment of Alzheimer’s disease